Show simple item record

dc.contributor.authorObianyo, Obiamaka
dc.contributor.authorOsborne, Tanesha C.
dc.contributor.authorThompson, Paul R
dc.date2022-08-11T08:11:00.000
dc.date.accessioned2022-08-23T17:28:20Z
dc.date.available2022-08-23T17:28:20Z
dc.date.issued2008-09-30
dc.date.submitted2015-06-03
dc.identifier.citationBiochemistry. 2008 Sep 30;47(39):10420-7. doi: 10.1021/bi800904m. <a href="http://dx.doi.org/10.1021/bi800904m">Link to article on publisher's site</a>. Epub 2008 Sep 5.
dc.identifier.issn0006-2960 (Linking)
dc.identifier.doi10.1021/bi800904m
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50058
dc.description<p>At the time of publication, Paul Thompson was not yet affiliated with UMass Medical School.</p>
dc.description.abstractProtein arginine methyltransferases (PRMTs) are SAM-dependent enzymes that catalyze the mono- and dimethylation of peptidyl arginine residues. Although all PRMTs produce monomethyl arginine (MMA), type 1 PRMTs go on to form asymmetrically dimethylated arginine (ADMA), while type 2 enzymes form symmetrically dimethylated arginine (SDMA). PRMT1 is the major type 1 PRMT in vivo, thus it is the primary producer of the competitive NOS inhibitor, ADMA. Hence, potent inhibitors, which are highly selective for this particular isozyme, could serve as excellent therapeutics for heart disease. However, the design of such inhibitors is impeded by a lack of information regarding this enzyme's kinetic and catalytic mechanisms. Herein we report an analysis of the kinetic mechanism of human PRMT1 using both an unmethylated and a monomethylated substrate peptide based on the N-terminus of histone H4. The results of initial velocity and product and dead-end inhibition experiments indicate that PRMT1 utilizes a rapid equilibrium random mechanism with the formation of dead-end EAP and EBQ complexes. This mechanism is gratifyingly consistent with previous results demonstrating that PRMT1 catalyzes substrate dimethylation in a partially processive manner.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18771293&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933744/
dc.subjectCatalysis
dc.subjectHeart Diseases
dc.subjectHumans
dc.subjectIsoenzymes
dc.subjectKinetics
dc.subjectMethylation
dc.subjectPeptide Fragments
dc.subjectProtein-Arginine N-Methyltransferases
dc.subjectpurification
dc.subjectBiochemistry
dc.subjectEnzymes and Coenzymes
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectTherapeutics
dc.titleKinetic mechanism of protein arginine methyltransferase 1
dc.typeJournal Article
dc.source.journaltitleBiochemistry
dc.source.volume47
dc.source.issue39
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/thompson/65
dc.identifier.contextkey7172284
html.description.abstract<p>Protein arginine methyltransferases (PRMTs) are SAM-dependent enzymes that catalyze the mono- and dimethylation of peptidyl arginine residues. Although all PRMTs produce monomethyl arginine (MMA), type 1 PRMTs go on to form asymmetrically dimethylated arginine (ADMA), while type 2 enzymes form symmetrically dimethylated arginine (SDMA). PRMT1 is the major type 1 PRMT in vivo, thus it is the primary producer of the competitive NOS inhibitor, ADMA. Hence, potent inhibitors, which are highly selective for this particular isozyme, could serve as excellent therapeutics for heart disease. However, the design of such inhibitors is impeded by a lack of information regarding this enzyme's kinetic and catalytic mechanisms. Herein we report an analysis of the kinetic mechanism of human PRMT1 using both an unmethylated and a monomethylated substrate peptide based on the N-terminus of histone H4. The results of initial velocity and product and dead-end inhibition experiments indicate that PRMT1 utilizes a rapid equilibrium random mechanism with the formation of dead-end EAP and EBQ complexes. This mechanism is gratifyingly consistent with previous results demonstrating that PRMT1 catalyzes substrate dimethylation in a partially processive manner.</p>
dc.identifier.submissionpaththompson/65
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages10420-7


This item appears in the following Collection(s)

Show simple item record